Literature DB >> 18184371

Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques.

S Kumar-Singh1.   

Abstract

Cerebral amyloid angiopathy (CAA) of the amyloid-beta (Abeta) type is the most common form of sporadic CAA and is now also accepted as an early and integral part of Alzheimer's disease (AD) pathogenesis. Cerebral amyloid angiopathy is a risk factor for haemorrhagic stroke and is believed to independently contribute to dementia. Rare forms of hereditary cerebral amyloidosis caused by mutations within the Abeta domain of amyloid precursor protein (APP) have been identified, where mutant Abeta preferably deposits in vessels because of a decreased fibrillogenic potential and/or increased vasotopicity. A review of factors involved in CAA caused by wild-type Abeta suggests that increased Abeta levels in brain without an increased Abeta42/Abeta40 ratio is one of the most important prerequisites for vascular amyloidosis. This is exemplified by CAA observed in APP duplication and Down's syndrome patients, neprilysin polymorphism patients and knockout mice and Swedish APP (KM670/671NL) mice. Select presenilin mutations also lead to a prominent CAA, and importantly, presenilin mutations are shown to have varied effects on the production of Abeta40, the predominant amyloid found in CAA. Conversely, APP mutations such as Austrian APP (T714I) drastically decrease Abeta40 production and are deficient in CAA. Apolipoprotein E-epsilon4 is also shown to be a risk factor for CAA, and this might be because of its specific role in the aggregation of Abeta40. Recent data also suggest that dense-core senile plaques in humans and dense plaques in transgenic mice, composed predominantly of Abeta40, associate with vessels. This review highlights some of these aspects of genetics and biochemistry of CAA and pathological descriptions linked to a prominent CAA and/or dense plaques in humans and relevant mouse models and discusses how this knowledge has led to a better understanding of the processes involved in vascular amyloidosis, and in causing dementia, and thus has important therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18184371     DOI: 10.1111/j.1601-183X.2007.00380.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  35 in total

1.  Tol2 gene trap integrations in the zebrafish amyloid precursor protein genes appa and aplp2 reveal accumulation of secreted APP at the embryonic veins.

Authors:  Hsin-Kai Liao; Ying Wang; Kristin E Noack Watt; Qin Wen; Justin Breitbach; Chelsy K Kemmet; Karl J Clark; Stephen C Ekker; Jeffrey J Essner; Maura McGrail
Journal:  Dev Dyn       Date:  2012-02       Impact factor: 3.780

2.  Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged AβPP/PS1 double transgenic mice.

Authors:  Thomas van Groen; Inga Kadish; Susanne Aileen Funke; Dirk Bartnik; Dieter Willbold
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

3.  Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease.

Authors:  Weiguo Peng; Thiyagarajan M Achariyar; Baoman Li; Yonghong Liao; Humberto Mestre; Emi Hitomi; Sean Regan; Tristan Kasper; Sisi Peng; Fengfei Ding; Helene Benveniste; Maiken Nedergaard; Rashid Deane
Journal:  Neurobiol Dis       Date:  2016-05-24       Impact factor: 5.996

4.  Contact sport participation and chronic traumatic encephalopathy are associated with altered severity and distribution of cerebral amyloid angiopathy.

Authors:  Oliver J Standring; Jacob Friedberg; Yorghos Tripodis; Alicia S Chua; Jonathan D Cherry; Victor E Alvarez; Bertrand R Huber; Weiming Xia; Jesse Mez; Michael L Alosco; Raymond Nicks; Ian Mahar; Morgan J Pothast; Hannah M Gardner; Gaoyuan Meng; Joseph N Palmisano; Brett M Martin; Brigid Dwyer; Neil W Kowall; Robert C Cantu; Lee E Goldstein; Douglas I Katz; Robert A Stern; Ann C McKee; Thor D Stein
Journal:  Acta Neuropathol       Date:  2019-06-10       Impact factor: 17.088

5.  Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer's disease mutations.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Anne B Rocher; Athena Ching-Jung Wang; William G M Janssen; Tony Flores; Gissel M Perez; James Schmeidler; Dara L Dickstein; Patrick R Hof; Gregory A Elder
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

6.  Prolonged diet induced obesity has minimal effects towards brain pathology in mouse model of cerebral amyloid angiopathy: implications for studying obesity-brain interactions in mice.

Authors:  Le Zhang; Kalavathi Dasuri; Sun-Ok Fernandez-Kim; Annadora J Bruce-Keller; Linnea R Freeman; Jennifer K Pepping; Tina L Beckett; M Paul Murphy; Jeffrey N Keller
Journal:  Biochim Biophys Acta       Date:  2013-01-09

7.  The bradykinin B1 receptor regulates Aβ deposition and neuroinflammation in Tg-SwDI mice.

Authors:  Giselle F Passos; Rodrigo Medeiros; David Cheng; Vitaly Vasilevko; Frank M Laferla; David H Cribbs
Journal:  Am J Pathol       Date:  2013-03-05       Impact factor: 4.307

8.  Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.

Authors:  Rebecca F Rosen; Brian J Ciliax; Thomas S Wingo; Marla Gearing; Jeromy Dooyema; James J Lah; Jorge A Ghiso; Harry LeVine; Lary C Walker
Journal:  Acta Neuropathol       Date:  2009-08-19       Impact factor: 17.088

9.  Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers.

Authors:  Francisco J Gonzalez-Velasquez; Joseph A Kotarek; Melissa A Moss
Journal:  J Neurochem       Date:  2008-09-16       Impact factor: 5.372

10.  Novel cerebrovascular pathology in mice fed a high cholesterol diet.

Authors:  Sonia Franciosi; Miguel A Gama Sosa; Daniel F English; Elizabeth Oler; Twethida Oung; William Gm Janssen; Rita De Gasperi; James Schmeidler; Dara L Dickstein; Christoph Schmitz; Sam Gandy; Patrick R Hof; Joseph D Buxbaum; Gregory A Elder
Journal:  Mol Neurodegener       Date:  2009-10-24       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.